Michael studied biology at the Carl von Ossietzky Universität in Oldenburg, Germany, from 1993-1999.
He received his PhD from the Leibniz Universität in Hannover, Germany, in 2002.
Since end of 2002 he is working as group leader at the Technische Universität Braunschweig, Germany.
In 2011, he finished his professorial dissertation (Habilitation, venia legendi for Biotechnology) and was appointed as Privatdozent (PD).
In 2014 he was appointed as professor for biotechnology.
He published more than 140 articles and filed seven patents in the field of antibody engineering and phage display.
He is working on the development of recombinant antibodies for proteome research, diagnostics and therapy with a focus on pathogens and toxins.
Another field of work is the identification of biomarkers of pathogens using ORFeome phage display.
He co-founded three biotech companies, the mAb-Factory GmbH in 2007, YUMAB GmbH (www.yumab.com) in 2012 and recently Norden Vaccines GmbH in 2019.